{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,10]],"date-time":"2026-11-10T00:55:46Z","timestamp":1794272146812,"version":"4.9.0"},"reference-count":68,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2016,9,20]],"date-time":"2016-09-20T00:00:00Z","timestamp":1474329600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2016,9,20]],"date-time":"2016-09-20T00:00:00Z","timestamp":1474329600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Alz Res Therapy"],"published-print":{"date-parts":[[2016,12]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:p>The global impact of Alzheimer\u2019s disease (AD) continues to increase, and focused efforts are needed to address this immense public health challenge. National leaders have set a goal to prevent or effectively treat AD by 2025. In this paper, we discuss the path to 2025, and what is feasible in this time frame given the realities and challenges of AD drug development, with a focus on disease-modifying therapies (DMTs). Under the current conditions, only drugs currently in late Phase 1 or later will have a chance of being approved by 2025. If pipeline attrition rates remain high, only a few compounds at best will meet this time frame. There is an opportunity to reduce the time and risk of AD drug development through an improvement in trial design; better trial infrastructure; disease registries of well-characterized participant cohorts to help with more rapid enrollment of appropriate study populations; validated biomarkers to better detect disease, determine risk and monitor disease progression as well as predict disease response; more sensitive clinical assessment tools; and faster regulatory review. To implement change requires efforts to build awareness, educate and foster engagement; increase funding for both basic and clinical research; reduce fragmented environments and systems; increase learning from successes and failures; promote data standardization and increase wider data sharing; understand AD at the basic biology level; and rapidly translate new knowledge into clinical development. Improved mechanistic understanding of disease onset and progression is central to more efficient AD drug development and will lead to improved therapeutic approaches and targets. The opportunity for more than a few new therapies by 2025 is small. Accelerating research and clinical development efforts and bringing DMTs to market sooner would have a significant impact on the future societal burden of AD. As these steps are put in place and plans come to fruition, e.g., approval of a DMT, it can be predicted that momentum will build, the process will be self-sustaining, and the path to 2025, and beyond, becomes clearer.<\/jats:p>","DOI":"10.1186\/s13195-016-0207-9","type":"journal-article","created":{"date-parts":[[2016,9,13]],"date-time":"2016-09-13T14:06:21Z","timestamp":1473775581000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":416,"title":["Drug development in Alzheimer\u2019s disease: the path to 2025"],"prefix":"10.1186","volume":"8","author":[{"given":"Jeffrey","family":"Cummings","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paul S.","family":"Aisen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bruno","family":"DuBois","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lutz","family":"Fr\u00f6lich","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"suffix":"Jr","given":"Clifford R.","family":"Jack","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Roy W.","family":"Jones","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"John C.","family":"Morris","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joel","family":"Raskin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sherie A.","family":"Dowsett","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Philip","family":"Scheltens","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2016,9,20]]},"reference":[{"key":"207_CR1","unstructured":"Alzheimer\u2019s Disease International, 2015. https:\/\/www.alz.co.uk\/research\/WorldAlzheimerReport2015.pdf. Accessed 25 May 2016."},{"key":"207_CR2","doi-asserted-by":"publisher","first-page":"73","DOI":"10.1586\/14737175.2015.995638","volume":"15","author":"G Vradenburg","year":"2015","unstructured":"Vradenburg G. A pivotal moment in Alzheimer\u2019s disease and dementia: how global unity of purpose and action can beat the disease by 2025. Expert Rev Neurother. 2015;15:73\u201382. Erratum: Expert Rev Neurother. 2015;15:459.","journal-title":"Expert Rev Neurother"},{"key":"207_CR3","unstructured":"National Alzheimer\u2019s Project Act. http:\/\/napa.alz.org\/national-alzheimers-project-act-backgroun. Accessed 25 May 2016."},{"key":"207_CR4","doi-asserted-by":"publisher","first-page":"251","DOI":"10.1111\/joim.12191","volume":"275","author":"LS Schneider","year":"2014","unstructured":"Schneider LS, Mangialasche F, Adreasen N, Feldman H, Giacobini E, Jones R, et al. Clinical trials and late-stage drug development for Alzheimer\u2019s disease: an appraisal from 1984 to 2014. J Intern Med. 2014;275:251\u201383.","journal-title":"J Intern Med."},{"key":"207_CR5","doi-asserted-by":"publisher","first-page":"37","DOI":"10.1186\/alzrt269","volume":"6","author":"JL Cummings","year":"2014","unstructured":"Cummings JL, Morstorf T, Zhong K. Alzheimer\u2019s disease drug-development pipeline: few candidates, frequent failures. Alz Res Ther. 2014;6:37.","journal-title":"Alz Res Ther."},{"key":"207_CR6","doi-asserted-by":"publisher","first-page":"388","DOI":"10.1016\/j.jalz.2009.07.038","volume":"5","author":"LS Schneider","year":"2009","unstructured":"Schneider LS, Sano M. Current Alzheimer\u2019s disease clinical trials: methods and placebo outcomes. Alzheimers Dement. 2009;5:388\u201397.","journal-title":"Alzheimers Dement."},{"key":"207_CR7","first-page":"216","volume":"2","author":"E Siemers","year":"2015","unstructured":"Siemers E. Drug development in AD: point of view from the industry. J Prev Alz Dis. 2015;2:216\u20138.","journal-title":"J Prev Alz Dis."},{"key":"207_CR8","doi-asserted-by":"publisher","first-page":"2021","DOI":"10.1185\/03007995.2014.939167","volume":"10","author":"DB Henley","year":"2014","unstructured":"Henley DB, Sundell KL, Sethuraman G, Dowsett SA, May PC. Safety profile of semagacestat, a gamm-secretase inhibitor: IDENTITY trial findings. Curr Med Res Opin. 2014;10:2021\u201332.","journal-title":"Curr Med Res Opin."},{"key":"207_CR9","doi-asserted-by":"publisher","first-page":"1632","DOI":"10.1016\/j.clinthera.2015.07.006","volume":"37","author":"H Sugino","year":"2015","unstructured":"Sugino H, Watanabe A, Amada N, Yamamoto M, Ohgi Y, Kostic D, Sanchez R. Global trends in Alzheimer disease clinical development: increasing the probability of success. Clin Ther. 2015;37:1632\u201342.","journal-title":"Clin Ther."},{"key":"207_CR10","doi-asserted-by":"publisher","first-page":"926","DOI":"10.1016\/S1474-4422(15)00153-2","volume":"14","author":"S Andrieu","year":"2015","unstructured":"Andrieu S, Coley N, Lovestone S, Aisen PS, Vellas B. Prevention of sporadic Alzheimer\u2019s disease: lessons learned from clinical trials and future directions. Lancet Neurol. 2015;14:926\u201344.","journal-title":"Lancet Neurol."},{"key":"207_CR11","doi-asserted-by":"publisher","first-page":"270","DOI":"10.1016\/j.jalz.2011.03.008","volume":"7","author":"MS Albert","year":"2011","unstructured":"Albert MS, DeKosky ST, Dickson D, Dubois B, Feldman HH, Fox NC, et al. The diagnosis of mild cognitive impairment due to Alzheimer\u2019s disease: recommendations from the National Institute on Aging-Alzheimer\u2019s Association workgroups on diagnostic guidelines for Alzheimer\u2019s disease. Alzheimers Dement. 2011;7:270\u20139.","journal-title":"Alzheimers Dement."},{"key":"207_CR12","doi-asserted-by":"publisher","first-page":"614","DOI":"10.1016\/S1474-4422(14)70090-0","volume":"13","author":"B Dubois","year":"2014","unstructured":"Dubois B, Feldman HH, Jacova C, Hampel H, Molinuevo JL, Blennow K, DeKosky ST, et al. Advancing research diagnostic criteria for Alzheimer\u2019s disease: the IWG-2 criteria. Lancet Neurol. 2014;13:614\u201329. Erratum in: Lancet Neurol. 2014;13:757.","journal-title":"Lancet Neurol"},{"key":"207_CR13","unstructured":"Scott TJ, O\u2019Connor AC, Link AN, Beaulieu TJ. Economic analysis of opportunities to accelerate Alzheimer\u2019s disease research and development. New York Academy of Sciences. 2013. http:\/\/onlinelibrary.wiley.com\/doi\/10.1111\/nyas.12417\/epdf. Accessed 25 May 2016."},{"key":"207_CR14","unstructured":"ALZFORUM therapeutics database. http:\/\/www.alzforum.org\/therapeutics. Accessed 25 May 2016."},{"key":"207_CR15","doi-asserted-by":"publisher","first-page":"505","DOI":"10.1016\/S0140-6736(15)01124-1","volume":"388","author":"P Scheltens","year":"2016","unstructured":"Scheltens P, Blennow K, Breteler MM, de Strooper B, Frisoni GB, Salloway S, Van der Flier WM. Alzheimer\u2019s disease. Lancet. 2016;388:505\u201317.","journal-title":"Lancet."},{"key":"207_CR16","doi-asserted-by":"publisher","first-page":"623","DOI":"10.1016\/j.jalz.2016.02.007","volume":"12","author":"JA Hendrix","year":"2016","unstructured":"Hendrix JA, Bateman RJ, Brashear HR, Duggan C, Carrillo MC, Bain LJ, et al. Challenges, solutions, and recommendations for Alzheimer\u2019s disease combination therapy. Alzheimers Dement. 2016;12:623\u201330.","journal-title":"Alzheimers Dement."},{"key":"207_CR17","unstructured":"The Alzheimer\u2019s Prevention Registry. https:\/\/www.endalznow.org\/. Accessed 25 May 2016."},{"key":"207_CR18","unstructured":"The Dominantly Inherited Alzheimer Network (DIAN). https:\/\/dian-tu.wustl.edu\/en\/about-dian-trials-unit\/. Accessed 25 May 2016."},{"key":"207_CR19","unstructured":"The Brain Health Registry. http:\/\/www.brainhealthregistry.org\/. Accessed 25 May 2016."},{"key":"207_CR20","unstructured":"The Global Alzheimer\u2019s Platform Initiative. www.globalalzplatform.org. Accessed 25 May 2016."},{"key":"207_CR21","first-page":"114","volume":"3","author":"J Cumming","year":"2016","unstructured":"Cumming J, Aisen P, Barton R, Bork J, Doody R, Dwyer J, et al. Re-engineering Alzheimer clinical trials: Global Alzheimer\u2019s Platform network. J Prev Alz Dis. 2016;3:114\u201320.","journal-title":"J Prev Alz Dis."},{"key":"207_CR22","unstructured":"The Cleveland Clinic Healthy Brains Registry available at https:\/\/healthybrains.org\/. Accessed 25 May 2016."},{"key":"207_CR23","unstructured":"The Alzheimer\u2019s Disease Cooperative Study. http:\/\/www.adcs.org\/. Accessed 25 May 2016."},{"key":"207_CR24","unstructured":"The Join Dementia Research Initiative. https:\/\/www.joindementiaresearch.nihr.ac.uk. Accessed 25 May 2016."},{"key":"207_CR25","doi-asserted-by":"crossref","first-page":"721","DOI":"10.3233\/JAD-2011-112202","volume":"28","author":"S Gillette-Guyonneta","year":"2012","unstructured":"Gillette-Guyonneta S, Vellas B. The Toulouse G\u00e9rontop\u00f4le Research Center: report of activities, 2007\u20132011. J Alzheimers Dis. 2012;28:721\u201332.","journal-title":"J Alzheimers Dis."},{"key":"207_CR26","doi-asserted-by":"crossref","first-page":"313","DOI":"10.3233\/JAD-132306","volume":"41","author":"WM van der Flier","year":"2014","unstructured":"van der Flier WM, Pijnenburg YA, Prins N, Lemstra AW, Bouwman FH, Teunissen CE, et al. Optimizing patient care and research: the Amsterdam Dementia Cohort. J Alzheimers Dis. 2014;41:313\u201327.","journal-title":"J Alzheimers Dis."},{"key":"207_CR27","doi-asserted-by":"publisher","first-page":"404","DOI":"10.1159\/000210388","volume":"27","author":"J Kornhuber","year":"2009","unstructured":"Kornhuber J, Schmidtke K, Frolich L, Perneczky R, Wolf S, Hampel H, et al. Early and differential diagnosis of dementia and mild cognitive impairment: design and cohort baseline characteristics of the German Dementia Competence Network. Dement Geriatr Cogn Disord. 2009;27:404\u201317.","journal-title":"Dement Geriatr Cogn Disord."},{"key":"207_CR28","doi-asserted-by":"publisher","first-page":"e73645","DOI":"10.1371\/journal.pone.0073645","volume":"8","author":"LB Zahodne","year":"2013","unstructured":"Zahodne LB, Manly JJ, MacKay-Brandt A, Stern Y. Cognitive declines precede and predict functional declines in aging and Alzheimer\u2019s disease. PLoS One. 2013;8:e73645.","journal-title":"PLoS One."},{"key":"207_CR29","first-page":"949","volume":"43","author":"H Liu-Seifert","year":"2015","unstructured":"Liu-Seifert H, Siemers E, Sundell K, Price K, Han B, Selzler K, et al. Cognitive and functional decline and their relationship in patients with mild Alzheimer\u2019s dementia. J Alz Dis. 2015;43:949\u201355.","journal-title":"J Alz Dis."},{"key":"207_CR30","doi-asserted-by":"publisher","first-page":"246","DOI":"10.1016\/S1474-4422(04)00710-0","volume":"3","author":"B Dubois","year":"2004","unstructured":"Dubois B, Albert ML. Amnestic MCI or prodromal Alzheimer\u2019s disease? Lancet Neurol. 2004;3:246\u20138.","journal-title":"Lancet Neurol."},{"key":"207_CR31","doi-asserted-by":"publisher","first-page":"1859","DOI":"10.1212\/01.wnl.0000279336.36610.f7","volume":"69","author":"M Sarazin","year":"2007","unstructured":"Sarazin M, Berr C, De Rotrou J, Fabrigoule C, Pasquier F, Legrain S, et al. Amnestic syndrome of the medial temporal type identifies prodromal AD: a longitudinal study. Neurology. 2007;69:1859\u201367.","journal-title":"Neurology."},{"key":"207_CR32","doi-asserted-by":"publisher","first-page":"379","DOI":"10.1212\/WNL.0b013e318245f447","volume":"78","author":"M Wagner","year":"2012","unstructured":"Wagner M, Wolf S, Reischies FM, Daerr M, Wolfsgruber S, Jessen F, et al. Biomarker validation of a cued recall memory deficit in prodromal Alzheimer disease. Neurology. 2012;78:379\u201386.","journal-title":"Neurology."},{"key":"207_CR33","first-page":"7","volume":"18","author":"K Jekel","year":"2015","unstructured":"Jekel K, Damian M, Wattmo C, Hausner L, Bullock R, Connelly PJ, et al. Mild cognitive impairment and deficits in instrumental activities of daily living: a systematic review. Alzheimers Res Ther. 2015;18:7\u201317.","journal-title":"Alzheimers Res Ther."},{"key":"207_CR34","unstructured":"US Department of Health and Human Services Food and Drug Administration Center for Drug Evaluation and Research (CDER). Draft guidance for industry - Alzheimer\u2019s disease: developing drugs for the treatment of early stage disease. Feb 2013. http:\/\/www.fda.gov\/downloads\/Drugs\/GuidanceComplianceRegulatoryInformation\/Guidances\/UCM338287.pdf. Accessed 25 May 2016."},{"key":"207_CR35","doi-asserted-by":"publisher","first-page":"961","DOI":"10.1001\/jamaneurol.2014.803","volume":"71","author":"MC Donohue","year":"2014","unstructured":"Donohue MC, Sperling RA, Salmon DP, Rentz DM, Raman R, Thomas RG, et al. Australian Imaging, Biomarkers, and Lifestyle Flagship Study of Ageing, Alzheimer\u2019s Disease Neuroimaging Initiative, Alzheimer\u2019s Disease Cooperative Study. The preclinical Alzheimer cognitive composite: measuring amyloid-related decline. JAMA Neurol. 2014;71:961\u201370.","journal-title":"JAMA Neurol"},{"key":"207_CR36","first-page":"227","volume":"2","author":"AM Wessels","year":"2015","unstructured":"Wessels AM, Siemers ER, Yu P, Andersen SW, Holdridge KC, Sims JR, et al. A combined measure of cognition and function for clinical trials: the integrated Alzheimer\u2019s disease rating scale. J Prev Alz Dis. 2015;2:227\u201341.","journal-title":"J Prev Alz Dis."},{"key":"207_CR37","doi-asserted-by":"publisher","first-page":"993","DOI":"10.1136\/jnnp-2015-312383","volume":"87","author":"J Wang","year":"2016","unstructured":"Wang J, Logovinsky V, Hendrix SB, Stanworth SH, Perdomo C, Xu L, et al. ADCOMS: a composite clinical outcome for prodromal Alzheimer\u2019s disease trials. J Neurol Neurosurg Psychiatry. 2016;87:993\u20139.","journal-title":"J Neurol Neurosurg Psychiatry."},{"key":"207_CR38","doi-asserted-by":"publisher","first-page":"673","DOI":"10.1016\/S1474-4422(16)00070-3","volume":"15","author":"B Olsson","year":"2016","unstructured":"Olsson B, Lautner R, Andreasson U, \u00d6hrfelt A, Portelius E, Bjerke M, et al. CSF and blood biomarkers for the diagnosis of Alzheimer\u2019s disease: a systematic review and meta-analysis. Lancet Neurol. 2016;15:673\u201384.","journal-title":"Lancet Neurol."},{"key":"207_CR39","doi-asserted-by":"publisher","first-page":"110","DOI":"10.1016\/j.jalz.2015.06.1893","volume":"12","author":"ER Siemers","year":"2016","unstructured":"Siemers ER, Sundell KL, Carlson C, Case M, Sethuraman G, Liu-Seifert H, et al. Phase 3 solanezumab trials: secondary outcomes in mild Alzheimer\u2019s disease patients. Alzheimers Dement. 2016;12:110\u201320.","journal-title":"Alzheimers Dement."},{"key":"207_CR40","doi-asserted-by":"crossref","first-page":"199","DOI":"10.1002\/ana.23931","volume":"74","author":"RC Petersen","year":"2013","unstructured":"Petersen RC, Aisen P, Boeve BF, Geda YE, Ivnik RJ, Knopman DS, et al. Criteria for mild cognitive impairment due to alzheimer\u2019s disease in the community. Ann Neurol. 2013;74:199\u2013208.","journal-title":"Ann Neurol."},{"key":"207_CR41","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1159\/000345791","volume":"35","author":"BS Appleby","year":"2013","unstructured":"Appleby BS, Nacopoulos D, Milano N, Zhong K, Cummings JL. A review: treatment of Alzheimer\u2019s disease discovered in repurposed agents. Dement Geriatr Cogn Disord. 2013;35:1\u201322.","journal-title":"Dement Geriatr Cogn Disord."},{"key":"207_CR42","doi-asserted-by":"publisher","first-page":"2306","DOI":"10.2174\/15680266113136660162","volume":"13","author":"BS Appleby","year":"2013","unstructured":"Appleby BS, Cummings JL. Discovering new treatments for Alzheimer\u2019s disease by repurposing approved medications. Curr Top Med Chem. 2013;13:2306\u201327.","journal-title":"Curr Top Med Chem."},{"key":"207_CR43","doi-asserted-by":"publisher","first-page":"4","DOI":"10.1186\/s13195-016-0173-2","volume":"8","author":"JL Cummings","year":"2016","unstructured":"Cummings JL, Zhong K, Kinney JW, Heaney C, Moll-Tudla J, Joshi A, et al. Double-blind, placebo-controlled, proof-of-concept trial of bexarotene in moderate Alzheimer\u2019s disease. Alz Res Ther. 2016;8:4.","journal-title":"Alz Res Ther."},{"key":"207_CR44","doi-asserted-by":"publisher","first-page":"E2895","DOI":"10.1073\/pnas.1121081109","volume":"109","author":"PE Sanchez","year":"2012","unstructured":"Sanchez PE, Zhu L, Verret L, Vossel KA, Orr AG, Cirrito JR, Devidze N, Ho K, Yu GQ, Palop JJ, Mucke L. Levetiracetam suppresses neuronal network dysfunction and reverses synaptic and cognitive deficits in an Alzheimer\u2019s disease model. Proc Natl Acad Sci U S A. 2012;109:E2895\u2013903.","journal-title":"Proc Natl Acad Sci U S A."},{"key":"207_CR45","doi-asserted-by":"publisher","first-page":"161","DOI":"10.1586\/17512433.2014.884923","volume":"7","author":"JL Cummings","year":"2014","unstructured":"Cummings JL, Zhong K. Repackaging FDA-approved drugs for degenerative diseases: promises and challenges. Expert Rev Clin Pharmacol. 2014;7:161\u20135.","journal-title":"Expert Rev Clin Pharmacol."},{"key":"207_CR46","unstructured":"European Medicines Agency Committee for Medicinal Products for Human Use. Draft guideline on the clinical investigation of medicines for the treatment of Alzheimer\u2019s disease and other dementias. Jan 2016 (EMA\/CHMP\/539931\/2014). http:\/\/www.ema.europa.eu\/docs\/en_GB\/document_library\/Scientific_guideline\/2016\/02\/WC500200830.pdf. Accessed 25 May 2016."},{"key":"207_CR47","unstructured":"CDER New Drug Review: 2015 Update. FDA\/CMS Summit 2014. http:\/\/www.fda.gov\/downloads\/AboutFDA\/CentersOffices\/OfficeofMedicalProductsandTobacco\/CDER\/UCM477020.pdf slide 20. Accessed 25 May 2016."},{"key":"207_CR48","volume-title":"White Paper: FDA and accelerating the development of the new pharmaceutical therapies","author":"US Food","year":"2015","unstructured":"Food US, Administration D. White Paper: FDA and accelerating the development of the new pharmaceutical therapies. 2015. http:\/\/www.fda.gov\/AboutFDA\/ReportsManualsForms\/Reports\/ucm439082.htm. Accessed 25 May 2016."},{"key":"207_CR49","first-page":"152","volume":"15","author":"M Shea","year":"2016","unstructured":"Shea M, Ostermann L, Hohman R, Roberts S, Kozak M, Dull R, et al. Impact of breakthrough therapy designation on cancer drug development. Nature. 2016;15:152.","journal-title":"Nature."},{"key":"207_CR50","unstructured":"European Medicines Agency Committee for Medicinal Products for Human Use. Draft guideline on the scientific application and the practical arrangements necessary to implement the procedure for accelerated assessment pursuant to article 14(9) of regulation (EC) No 726\/2004 7. Jul 2015 (EMA\/CHMP\/697051\/2014-Rev). http:\/\/ec.europa.eu\/health\/files\/committee\/stamp\/2015-10_stamp3\/stamp_3_16_3b_guideline_on_accelerated_assessment_-_public_consultation.pdf. Accessed 25 May 2016."},{"key":"207_CR51","doi-asserted-by":"crossref","unstructured":"Cummings JL, Morstorf T, Lee G. Alzheimer\u2019s drug development pipeline: 2016. Alzheimers Dement. 2016 (in press).","DOI":"10.1016\/j.trci.2016.07.001"},{"key":"207_CR52","doi-asserted-by":"publisher","first-page":"1481","DOI":"10.1001\/jamaneurol.2014.2482","volume":"71","author":"Q Liu","year":"2014","unstructured":"Liu Q, Waltz S, Woodruff G, Ouyang J, Israel MA, Herrera C, et al. Effect of potent-secretase modulator in human neurons derived from multiple presenilin 1-induced pluripotent stem cell mutant carriers. JAMA Neurol. 2014;71:1481\u20139.","journal-title":"JAMA Neurol."},{"key":"207_CR53","doi-asserted-by":"publisher","first-page":"274","DOI":"10.1038\/nature13800","volume":"515","author":"SH Choi","year":"2014","unstructured":"Choi SH, Kim YH, Hebisch M, Sliwinski C, Lee S, D'Avanzo C, et al. A three-dimensional human neural cell culture model of Alzheimer\u2019s disease. Nature. 2014;515:274\u20138.","journal-title":"Nature."},{"key":"207_CR54","unstructured":"Innovative Medicines Initiative. http:\/\/www.imi.europa.eu\/. Accessed 25 May 2016."},{"key":"207_CR55","unstructured":"Prediction of cognitive properties of new drug candidates for neurodegenerative diseases in early clinical development. http:\/\/www.alzheimer-europe.org\/EN\/Research\/PharmaCog. Accessed 25 May 2016."},{"key":"207_CR56","unstructured":"European Medical Information Framework Platform http:\/\/www.emif.eu\/. Accessed 25 May 2016."},{"key":"207_CR57","unstructured":"European Prevention of Alzheimer\u2019s Dementia (EPAD) Initiative. http:\/\/ep-ad.org\/. Accessed 25 May 2016."},{"key":"207_CR58","unstructured":"Critical Path Institute. https:\/\/c-path.org\/. Accessed 25 May 2016."},{"key":"207_CR59","doi-asserted-by":"publisher","first-page":"210","DOI":"10.1002\/cpt.16","volume":"97","author":"K Romero","year":"2015","unstructured":"Romero K, Ito K, Rogers JA, Polhamus D, Qiu R, Stephenson D, et al. The future is now: model\u2010based clinical trial design for Alzheimer\u2019s disease. Clin Pharmacol Ther. 2015;97:210\u20134.","journal-title":"Clin Pharmacol Ther."},{"key":"207_CR60","unstructured":"Global Alzheimer\u2019s Association Interactive Network. http:\/\/www.gaain.org\/. Accessed 25 May 2016."},{"key":"207_CR61","unstructured":"Accelerating Medicines Partnership - Alzheimer\u2019s Disease. https:\/\/www.nia.nih.gov\/alzheimers\/amp-ad. Accessed 25 May 2016."},{"key":"207_CR62","doi-asserted-by":"crossref","unstructured":"Tariot PN, Ho C, Langlois C, Reiman EM, Lopera F, Langbaum JB, et al. The Alzheimer\u2019s Prevention Initiative. Alzheimers Dement. 2014;10(4):247.","DOI":"10.1016\/j.jalz.2014.04.379"},{"key":"207_CR63","doi-asserted-by":"crossref","first-page":"1126","DOI":"10.1093\/jamia\/ocv077","volume":"22","author":"AW Toga","year":"2015","unstructured":"Toga AW, Foster I, Kesselman C, Madduri R, Chard K, Deutsch EW, et al. Big biomedical data as the key resource for discovery science. J Am Med Inform Assoc. 2015;22:1126\u201331.","journal-title":"J Am Med Inform Assoc."},{"key":"207_CR64","doi-asserted-by":"publisher","unstructured":"Haas M, Stephenson D, Romero K, Gordon M, Zach N, Geerts H; Brain Health Modeling Initiative. Big data to smart data in AD: real-world examples of advanced modeling and simulation. Alzheimers Dement. 2016. [Epub ahead of print]. doi: 10.1016\/j.jalz.2016.05.005.","DOI":"10.1016\/j.jalz.2016.05.005"},{"key":"207_CR65","doi-asserted-by":"publisher","unstructured":"Geerts H, Dacks PA, Devanarayan V, Haas M, Khachaturian Z, Gordon MF, Maudsley S, Romero K, Stephenson D; Brain Health Modeling Initiative (BHMI). From big data to smart data in Alzheimer\u2019s disease. The brain health modeling initiative to foster actionable knowledge. Alzheimers Dement. 2016. [Epub ahead of print]. doi: 10.1016\/j.jalz.2016.04.008.","DOI":"10.1016\/j.jalz.2016.04.008"},{"key":"207_CR66","unstructured":"The Alzheimer\u2019s Drug Discovery Foundation https:\/\/www.alzdiscovery.org\/. Accessed 25 May 2016."},{"key":"207_CR67","unstructured":"The Cure Alzheimer\u2019s Fund. http:\/\/www.curealz.org. Accessed 25 May 2016."},{"key":"207_CR68","unstructured":"Give To Cure. http:\/\/www.givetocure.org\/. Accessed 25 May 2016."}],"container-title":["Alzheimer's Research &amp; Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13195-016-0207-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s13195-016-0207-9\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13195-016-0207-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,1,31]],"date-time":"2022-01-31T04:32:33Z","timestamp":1643603553000},"score":1,"resource":{"primary":{"URL":"https:\/\/alzres.biomedcentral.com\/articles\/10.1186\/s13195-016-0207-9"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2016,9,20]]},"references-count":68,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2016,12]]}},"alternative-id":["207"],"URL":"https:\/\/doi.org\/10.1186\/s13195-016-0207-9","relation":{},"ISSN":["1758-9193"],"issn-type":[{"value":"1758-9193","type":"electronic"}],"subject":[],"published":{"date-parts":[[2016,9,20]]},"assertion":[{"value":"20 September 2016","order":1,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}}],"article-number":"39"}}